Company Overview
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to the identification, acquisition, development, and commercialization of novel products designed for the treatment of rare and ultra-rare genetic diseases. The company operates within the Healthcare sector and specifically the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles targeting specialized patient populations. The entity employs 1,371 individuals and holds a market capitalization of $1.92B while generating annual revenue of $673.00M. These valuation and revenue figures indicate that the company has achieved a significant operational scale within the niche rare disease market, positioning it as a substantial player despite the inherent challenges of commercializing therapies for small patient demographics across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific regions.
Financial Health
The company reported revenue of $673.00M for the trailing twelve months, yet recorded a net income of -$575,000,000 and an EBITDA of -$500,000,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely driven by research and development and commercialization costs, far exceed the gross revenue generated. Ultragenyx generated free cash flow of -$251,124,992, which indicates that the company is currently consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity. This negative cash flow suggests a reliance on external capital sources or existing cash balances to sustain financial flexibility during the development and launch phases of its pipeline. The company displays negative gross margins of -27.6%, negative operating margins of -54.7%, and negative profit margins of -85.4%, which collectively indicate that the business model is currently unprofitable on a per-unit basis and that costs are not being covered by sales. On the balance sheet, the company holds $680.00M in cash against $1.25B in debt, resulting in a debt-to-equity ratio listed as N/A due to the negative equity position. The current ratio stands at 2.48, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on Equity is reported at -608.5% and Return on Assets at -22.0%, metrics that reveal management is currently utilizing shareholder and asset bases to generate losses rather than positive returns.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is 245.58, implying that the market is pricing in significant future earnings growth to justify current valuations. The price-to-book ratio is -23.94, indicating that the market capitalization is negative relative to book value, a common characteristic for biotechnology firms with negative retained earnings. The price-to-sales ratio is 2.85 and the EV/EBITDA is -4.99, suggesting that valuation is being driven by revenue multiples rather than profitability or earnings power. The stock has traded between a 52-week high of $42.37 and a 52-week low of $18.41. Without the specific current share price provided in the available facts, the exact percentage below the 52-week high cannot be calculated, but the range demonstrates a wide trading band typical of volatile biotech equities. The beta value is 0.21, which means the stock price exhibits significantly lower volatility relative to the broader market, moving less than a third as much as the general market index.
Growth & Income
Revenue growth year-over-year is 25.9%, while earnings growth is N/A because the company is currently unprofitable. Since earnings are negative, they cannot be growing faster than revenue in the traditional sense, but the revenue expansion suggests successful commercialization or pipeline movement despite the lack of profitability. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which explains that the organization reinvests all available resources back into the business rather than distributing income to shareholders. The overall growth and income profile reflects a classic biotechnology company trajectory characterized by strong top-line revenue expansion, negative earnings, and a complete reinvestment of capital to fund future product development and market expansion.